Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project

The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasma(defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex. Design and Methods Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in 20 countries participating in EUROCARE-4 were analyzed. The period approach was used to estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5 years of follow up. Results: The 5-year relative survival rate was 57% overall but varied markedly between the defined groups. Variation in survival within the groups was relatively limited across European regions and less than in previous years. Survival differences between men and women were small. The relative survival for patients with all lymphoid neoplasms decreased substantially after the age of 50. The proportion of ‘not otherwise specified’ diagnoses increased with advancing age.Conclusions: This is the first study to analyze survival of patients with lymphoid neoplasms, divided into groups characterized by similar epidemiological and clinical characteristics, providing a benchmark for more detailed analyses. This Europe-wide study suggests that previously noted differences in survival between regions have tended to decrease. The survival of patients with all neoplasms decreased markedly with age, while the proportion of ‘not otherwise specified’ diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care decreased with age, suggesting that older patients may not be receiving optimal treatment

Empowerment: model i instrument de mesura basat en les variables primàries o efectives PIEQ (Primary Items Empowerment Questionnaire)

In this thesis a review of the state of the art on empowerment is found. A proposal is put forward for a model of the effective variables of empowerment, a new theoretical model that provides a distinct classification of individual variables. The model consists of four metavariables called reciprocal, unidirectional, shared and reflexive. Finally, a measurement tool for measuring and representing these variables graphically is described, including its process of elaboration through a preliminary pilot study that served to refine and improve the questionnaire. Both the model and the instrument proposed aim to determine the state of the primary variables involved in determining the predisposition and potential of a working group towards empowerment. With the measurement tool both organisational, departmental, working group and/or individual data can be obtained. This instrument can help companies and organisations to discover the limitations existing within a working group and act in consequence.

Contrafacção/falsificação de medicamentos

A panóplia de medicamentos e produtos de saúde existentes no mercado é enorme, existindo uma escolha alargada para os consumidores. Contudo, por vezes os preços são elevados; o medicamento que o consumidor quer não é legal no país onde se encontra; o consumidor, por vergonha, não se desloca a locais licenciados para comprar o medicamento que quer ou, o país ainda não tem acesso a um determinado medicamento inovador. E por estas razões o consumidor pode obter medicamentos falsificados através da cadeia ilegal de abastecimento, sendo a internet uma via provável de acesso. Contudo não é apenas na cadeia ilegal de abastecimento que se corre o risco de obter produtos falsificados. A cadeia de abastecimento legal tornou-se complexa e o controlo e fiscalização da mesma começou a ser mais difícil de realizar. Esta complexidade e o facto do sistema regulamentar não estar ainda bem implementado, levou ao aparecimento de produtos falsificados na cadeia legal. Para o controlo regulamentar deste problema, ao fim de alguns anos de debate e modificações à proposta existente, foi lançada na União Europeia a Directiva 2011/62/EU que pretende impedir a introdução de medicamentos falsificados na cadeia de abastecimento legal. A nível europeu existem iniciativas e organizações, tais como a International Medical Products Anti-Counterfeiting Taskforce(IMPACT), a Medicrime, Working Group of Enforcement Officers(WGEO), Pharmaceutical Security Institute(PSI), entre outras,cujo objectivo principal é o combate à contrafacção. São organizações e iniciativas com um grau de importância elevado devido ao trabalho que realizam. Para além destas acções as entidades reguladoras dos vários países europeus têm os Single Points of Contact (SPOCs) que permitem a troca de informação e colaboração internacional para que todos tenham acesso à mesma informação e a casos detectados. Em Portugal, o INFARMED I.P. é a Autoridade Nacional do Medicamento e Produtos de saúde e desta autoridade depende a fiscalização e controlo dos diversos intervenientes no ciclo do medicamento. Existe no INFARMED I.P. um departamento designado de Célula 3C que trabalha diariamente para o combate à contrafacção de medicamentos a nível nacional. São pontos essenciais no combate à contrafacção de medicamentos, que a Directiva seja implementada a nível nacional e que os esforços e cooperação entre os vários países perdurem para que haja uma diminuição do risco nos próximos anos.

MJO Simulation Diagnostics

The Madden–Julian oscillation (MJO) interacts with and influences a wide range of weather and climate phenomena (e.g., monsoons, ENSO, tropical storms, midlatitude weather), and represents an important, and as yet unexploited, source of predictability at the subseasonal time scale. Despite the important role of the MJO in climate and weather systems, current global circulation models (GCMs) exhibit considerable shortcomings in representing this phenomenon. These shortcomings have been documented in a number of multimodel comparison studies over the last decade. However, diagnosis of model performance has been challenging, and model progress has been difficult to track, because of the lack of a coherent and standardized set of MJO diagnostics. One of the chief objectives of the U.S. Climate Variability and Predictability (CLIVAR) MJO Working Group is the development of observation-based diagnostics for objectively evaluating global model simulations of the MJO in a consistent framework. Motivation for this activity is reviewed, and the intent and justification for a set of diagnostics is provided, along with specification for their calculation, and illustrations of their application. The diagnostics range from relatively simple analyses of variance and correlation to more sophisticated space–time spectral and empirical orthogonal function analyses. These diagnostic techniques are used to detect MJO signals, to construct composite life cycles, to identify associations of MJO activity with the mean state, and to describe interannual variability of the MJO.

The implications of projected climate change for freshwater resources and their management

A review of the implications of climate change for freshwater resources, based on Chapter 4 of Working Group 2, IPCC.